查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954288

鴉片類藥物市場分析及預測（至2035年）：類型、產品類型、用途、最終用戶、劑型、技術、通路、功能、設備

Opioids Market Analysis and Forecast to 2035: Type, Product, Application, End User, Form, Technology, Distribution Channel, Functionality, Equipment
出版日期: | 出版商: Global Insight Services | 英文 380 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

鴉片類藥物市場預計將從2024年的45億美元成長到2034年的67億美元，複合年成長率約為3%。鴉片類藥物市場涵蓋鴉片類藥物的生產、分銷和消費，這些藥物主要用於疼痛管理。該市場包括處方鴉片類藥物（如羥考酮和氫可酮）以及非法鴉片類藥物（如海洛因）。慢性疼痛病例和外科手術的增加是推動市場成長的主要因素，但同時也面臨監管限制和鴉片危機的挑戰。抗濫用製劑和替代疼痛療法的創新正在重塑市場動態，凸顯了在有效疼痛管理與降低濫用風險之間取得平衡的必要性。

由於監管環境的變化和對疼痛管理解決方案需求的不斷成長，鴉片類藥物市場正經歷動態轉型。處方鴉片類藥物佔據市場主導，其中羥考酮和氫可酮因其在慢性疼痛治療​​中的廣泛應用而成為表現最佳的細分市場。Buprenornhine作為部分致效劑，正迅速崛起，成為第二大細分市場，尤其是在成癮治療和管理領域。非法鴉片類藥物市場，特別是Fentanyl等合成鴉片類藥物，也經歷了顯著成長，但同時也面臨許多監管和倫理方面的挑戰。Fentanyl類似物因其強效作用和在非法市場的普遍存在，已成為該領域一個備受關注的重點。為了在有效緩解疼痛的同時降低濫用風險，人們越來越重視開發抗濫用製劑。非鴉片類鎮痛替代療法的創新也推動了市場的發展，為多元化和成長提供了廣泛的機會。

市場區隔
類型 天然的、半合成的、合成的
產品 可待因、Fentanyl、美沙酮、氫可酮、羥考酮、氫可酮、Buprenornhine、曲馬多
目的 疼痛管理、止咳、止瀉、成癮治療
最終用戶 醫院、診所、居家醫療機構、復健中心
劑型 片劑、膠囊、注射劑、貼片
科技 速釋、緩釋
通路 醫院藥局、零售藥局、網路藥局
功能 鎮痛藥、麻醉藥、鎮咳藥、止瀉藥
裝置 分配器、輸液泵

鴉片類藥物市場呈現出複雜的市場佔有率分佈格局，這主要受不斷演變的定價策略和創新產品的推出所驅動。儘管老牌製藥公司佔據主導地位，但新參與企業也憑藉新型製劑不斷取得進展。策略定價塑造了競爭格局，並且仍然是市場滲透的關鍵因素。近期推出的產品著重於提高療效和減少副作用，這反映出市場正朝著以患者為中心的解決方案轉變。這種動態環境凸顯了策略敏捷性和創新對於維持市場地位的重要性。鴉片類藥物市場的競爭異常激烈，主要參與者不斷相互比較，以保持競爭優勢。法規結構對市場動態有顯著影響，嚴格的指導方針影響產品開發和核准流程。北美仍然是領先的市場，這得益於監管政策的發展和旺盛的需求。然而，由於醫療保健投資的增加，亞太地區的成長正在加速。競爭與監管之間的相互作用既帶來了挑戰，也帶來了機遇，需要採取策略性方法來應對這個複雜的市場環境。

主要趨勢和促進因素：

由於監管政策的調整、醫療實踐的演變以及技術的進步，鴉片類藥物市場正經歷動態變化。其中一個關鍵趨勢是，各國政府和醫療機構越來越重視研發防濫用製劑，以應對全球鴉片危機，減少濫用和成癮問題。此外，對更安全止痛方案的需求促使人們對非鴉片類鎮痛替代方案越來越感興趣。科技創新發揮著至關重要的作用，數位健康工具和遠端醫療的進步正在增強疼痛管理策略。這些技術提供遠端監測和個人化治療方案，與醫療保健領域數位轉型的大趨勢相契合。此外，人口老化導致老年人慢性疼痛盛行率上升，從而催生了對有效疼痛管理方案的需求，顯著推動了市場成長。新興市場醫療基礎設施快速發展，蘊藏著許多機會。投資這些地區的公司有望受益於疼痛管理療法需求的成長。隨著相關人員尋求拓展產品系列併加強市場滲透，策略聯盟和夥伴關係也不斷增加。鴉片類藥物市場正在不斷發展，重點關注創新和永續實踐。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 自然的
    • 半合成
    • 合成
  • 市場規模及預測：依產品分類
    • 可待因
    • Fentanyl
    • 美沙酮
    • 氫可酮
    • 羥考酮
    • 氫可酮
    • Buprenornhine
    • 曲馬多
  • 市場規模及預測：依應用領域分類
    • 疼痛管理
    • 咳嗽治療
    • 腹瀉治療
    • 成癮治療
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 居家醫療環境
    • 復健中心
  • 市場規模及預測：依類型
    • 藥片
    • 膠囊
    • 注射
    • 修補
  • 市場規模及預測：依技術分類
    • 立即生效
    • 緩釋製劑
  • 市場規模及預測：依分銷通路分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場規模及預測：依功能分類
    • 止痛藥
    • 麻醉劑
    • 止咳藥
    • 止瀉藥
  • 市場規模及預測：依設備分類
    • 自動販賣機
    • 點滴幫浦

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Purdue Pharma
  • Mallinckrodt Pharmaceuticals
  • Endo International
  • Collegium Pharmaceutical
  • Assertio Therapeutics
  • Trevi Therapeutics
  • Egalet Corporation
  • Bio Delivery Sciences International
  • Insys Therapeutics
  • Alkermes
  • Pacira Bio Sciences
  • Zogenix
  • Acel Rx Pharmaceuticals
  • Cara Therapeutics
  • Nektar Therapeutics
  • Heron Therapeutics
  • Titan Pharmaceuticals
  • Elite Pharmaceuticals
  • Pain Therapeutics
  • Durect Corporation

第9章：關於我們

簡介目錄
Product Code: GIS26464

Opioids Market is anticipated to expand from $4.5 billion in 2024 to $6.7 billion by 2034, growing at a CAGR of approximately 3%. The Opioids Market encompasses the production, distribution, and consumption of opioid drugs, which are primarily used for pain management. This market includes both prescription opioids, such as oxycodone and hydrocodone, and illicit opioids like heroin. The market is driven by rising chronic pain cases and surgical procedures, yet faces challenges from regulatory restrictions and the opioid crisis. Innovations in abuse-deterrent formulations and alternative pain therapies are reshaping market dynamics, emphasizing the need for balance between effective pain management and minimizing abuse potential.

The Opioids Market is experiencing dynamic shifts, driven by evolving regulatory landscapes and increasing demand for pain management solutions. The prescription opioids segment dominates, with oxycodone and hydrocodone being the top-performing sub-segments due to their widespread use in chronic pain treatment. Emerging trends indicate that buprenorphine, a partial agonist, is gaining traction as the second-highest performing sub-segment, especially in addiction treatment and management. The illicit opioids segment, particularly synthetic opioids like fentanyl, is also witnessing significant growth, albeit with considerable regulatory and ethical challenges. Within this segment, fentanyl analogs are emerging as a critical area of concern due to their potency and prevalence in illicit markets. The focus on developing abuse-deterrent formulations is intensifying, as stakeholders seek to balance effective pain management with minimizing abuse potential. Innovations in non-opioid pain relief alternatives are also contributing to market evolution, presenting lucrative opportunities for diversification and growth.

Market Segmentation
TypeNatural, Semi-synthetic, Synthetic
ProductCodeine, Fentanyl, Methadone, Morphine, Oxycodone, Hydrocodone, Buprenorphine, Tramadol
ApplicationPain Management, Cough Treatment, Diarrhea Treatment, De-addiction
End UserHospitals, Clinics, Homecare Settings, Rehabilitation Centers
FormTablets, Capsules, Injectables, Patches
TechnologyImmediate-release, Extended-release
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies
FunctionalityAnalgesic, Anesthetic, Antitussive, Antidiarrheal
EquipmentDispensers, Infusion Pumps

The opioids market demonstrates a nuanced distribution of market share, influenced by evolving pricing strategies and the introduction of innovative products. Established pharmaceutical companies dominate, yet new entrants are making strides with novel formulations. The competitive landscape is shaped by strategic pricing, which remains a critical factor in market penetration. Recent product launches have focused on enhancing efficacy and reducing side effects, reflecting a shift towards patient-centric solutions. This dynamic environment underscores the importance of strategic agility and innovation in maintaining market relevance. Competition in the opioids market is intense, with major players continuously benchmarking against each other to maintain competitive advantages. Regulatory frameworks significantly impact market dynamics, with stringent guidelines influencing product development and approval processes. North America remains a key market, driven by regulatory advancements and high demand. However, the Asia-Pacific region is witnessing accelerated growth due to increasing healthcare investments. The interplay of competition and regulation presents both challenges and opportunities, necessitating a strategic approach to navigate this complex landscape.

Geographical Overview:

The global opioids market exhibits varied growth dynamics across regions, with distinct emerging opportunities. North America remains dominant, driven by a high prevalence of chronic pain and substantial healthcare expenditure. The region's regulatory landscape, focusing on responsible opioid use, continues to shape market growth. In Europe, the market is stable, supported by a well-established healthcare infrastructure and increasing awareness of pain management solutions. Asia Pacific is a burgeoning hub for market expansion, fueled by rising healthcare needs and improving medical infrastructure. Countries like India and China are at the forefront, driven by large populations and increasing healthcare access. The region's growing focus on modern pain management techniques offers lucrative opportunities for market players. Latin America and the Middle East & Africa are emerging as potential growth pockets. In Latin America, increasing healthcare investments and awareness of pain management are key drivers, while the Middle East & Africa are recognizing the importance of opioids in enhancing quality of life for patients.

The global opioid market is increasingly influenced by tariffs, geopolitical tensions, and supply chain dynamics. Japan and South Korea, traditionally reliant on US pharmaceutical imports, are diversifying supply sources to mitigate tariff impacts. China, amid trade restrictions, is bolstering its domestic pharmaceutical production capabilities, while Taiwan leverages its advanced manufacturing to remain competitive despite geopolitical risks. The parent market for pain management drugs is experiencing moderate growth, driven by aging populations and rising chronic pain incidences. By 2035, market evolution will hinge on regulatory harmonization and innovation in non-addictive analgesics. Middle East conflicts, while primarily affecting energy prices, indirectly pressure global supply chains, increasing production costs and affecting market stability, underscoring the need for strategic resilience and diversification.

Key Trends and Drivers:

The opioids market is experiencing dynamic shifts influenced by regulatory changes, evolving healthcare practices, and technological advancements. A key trend is the increasing emphasis on developing abuse-deterrent formulations. This is in response to the global opioid crisis, as governments and healthcare providers seek to mitigate misuse and addiction. Additionally, there is a growing focus on non-opioid pain management alternatives, driven by the need to provide safer pain relief solutions. Technological innovation plays a pivotal role, with advancements in digital health tools and telemedicine enhancing pain management strategies. These technologies offer remote monitoring and personalized treatment plans, aligning with the broader trend of digital transformation in healthcare. Furthermore, the aging population contributes significantly to market growth, as chronic pain conditions become more prevalent among older adults, necessitating effective pain management solutions. Opportunities abound in emerging markets where healthcare infrastructure is developing rapidly. Companies investing in these regions are likely to benefit from increased demand for pain management therapies. Strategic collaborations and partnerships are also on the rise, as stakeholders aim to broaden their product portfolios and enhance market reach. The opioids market is poised for evolution, with a focus on innovation and sustainable practices.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Form
  • 2.6 Key Market Highlights by Technology
  • 2.7 Key Market Highlights by Distribution Channel
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Natural
    • 4.1.2 Semi-synthetic
    • 4.1.3 Synthetic
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Codeine
    • 4.2.2 Fentanyl
    • 4.2.3 Methadone
    • 4.2.4 Morphine
    • 4.2.5 Oxycodone
    • 4.2.6 Hydrocodone
    • 4.2.7 Buprenorphine
    • 4.2.8 Tramadol
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Pain Management
    • 4.3.2 Cough Treatment
    • 4.3.3 Diarrhea Treatment
    • 4.3.4 De-addiction
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Rehabilitation Centers
  • 4.5 Market Size & Forecast by Form (2020-2035)
    • 4.5.1 Tablets
    • 4.5.2 Capsules
    • 4.5.3 Injectables
    • 4.5.4 Patches
  • 4.6 Market Size & Forecast by Technology (2020-2035)
    • 4.6.1 Immediate-release
    • 4.6.2 Extended-release
  • 4.7 Market Size & Forecast by Distribution Channel (2020-2035)
    • 4.7.1 Hospital Pharmacies
    • 4.7.2 Retail Pharmacies
    • 4.7.3 Online Pharmacies
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Analgesic
    • 4.8.2 Anesthetic
    • 4.8.3 Antitussive
    • 4.8.4 Antidiarrheal
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Dispensers
    • 4.9.2 Infusion Pumps

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Form
      • 5.2.1.6 Technology
      • 5.2.1.7 Distribution Channel
      • 5.2.1.8 Functionality
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Form
      • 5.2.2.6 Technology
      • 5.2.2.7 Distribution Channel
      • 5.2.2.8 Functionality
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Form
      • 5.2.3.6 Technology
      • 5.2.3.7 Distribution Channel
      • 5.2.3.8 Functionality
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Form
      • 5.3.1.6 Technology
      • 5.3.1.7 Distribution Channel
      • 5.3.1.8 Functionality
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Form
      • 5.3.2.6 Technology
      • 5.3.2.7 Distribution Channel
      • 5.3.2.8 Functionality
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Form
      • 5.3.3.6 Technology
      • 5.3.3.7 Distribution Channel
      • 5.3.3.8 Functionality
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Form
      • 5.4.1.6 Technology
      • 5.4.1.7 Distribution Channel
      • 5.4.1.8 Functionality
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Form
      • 5.4.2.6 Technology
      • 5.4.2.7 Distribution Channel
      • 5.4.2.8 Functionality
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Form
      • 5.4.3.6 Technology
      • 5.4.3.7 Distribution Channel
      • 5.4.3.8 Functionality
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Form
      • 5.4.4.6 Technology
      • 5.4.4.7 Distribution Channel
      • 5.4.4.8 Functionality
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Form
      • 5.4.5.6 Technology
      • 5.4.5.7 Distribution Channel
      • 5.4.5.8 Functionality
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Form
      • 5.4.6.6 Technology
      • 5.4.6.7 Distribution Channel
      • 5.4.6.8 Functionality
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Form
      • 5.4.7.6 Technology
      • 5.4.7.7 Distribution Channel
      • 5.4.7.8 Functionality
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Form
      • 5.5.1.6 Technology
      • 5.5.1.7 Distribution Channel
      • 5.5.1.8 Functionality
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Form
      • 5.5.2.6 Technology
      • 5.5.2.7 Distribution Channel
      • 5.5.2.8 Functionality
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Form
      • 5.5.3.6 Technology
      • 5.5.3.7 Distribution Channel
      • 5.5.3.8 Functionality
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Form
      • 5.5.4.6 Technology
      • 5.5.4.7 Distribution Channel
      • 5.5.4.8 Functionality
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Form
      • 5.5.5.6 Technology
      • 5.5.5.7 Distribution Channel
      • 5.5.5.8 Functionality
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Form
      • 5.5.6.6 Technology
      • 5.5.6.7 Distribution Channel
      • 5.5.6.8 Functionality
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Form
      • 5.6.1.6 Technology
      • 5.6.1.7 Distribution Channel
      • 5.6.1.8 Functionality
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Form
      • 5.6.2.6 Technology
      • 5.6.2.7 Distribution Channel
      • 5.6.2.8 Functionality
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Form
      • 5.6.3.6 Technology
      • 5.6.3.7 Distribution Channel
      • 5.6.3.8 Functionality
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Form
      • 5.6.4.6 Technology
      • 5.6.4.7 Distribution Channel
      • 5.6.4.8 Functionality
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Form
      • 5.6.5.6 Technology
      • 5.6.5.7 Distribution Channel
      • 5.6.5.8 Functionality
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Purdue Pharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Mallinckrodt Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Endo International
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Collegium Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Assertio Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Trevi Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Egalet Corporation
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bio Delivery Sciences International
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Insys Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Alkermes
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pacira Bio Sciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Zogenix
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Acel Rx Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cara Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Nektar Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Heron Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Titan Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Elite Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Pain Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Durect Corporation
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us